| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;105:1909.)
© 2002 American Heart Association, Inc.
Clinical Investigation and Reports |
From the TIMI Study Group, Department of Medicine, Brigham and Womens Hospital (C.M.G., S.A.M., S.J.M., C.P.C., E.B.), Boston, Mass, and the Cardiovascular Division, Department of Medicine, the University of California San Francisco (H.V.B.).
Correspondence to C. Michael Gibson, MS, MD, TIMI Study Group, 930 Commonwealth Ave, 3rd Floor, Boston, MA 02215. E-mail mgibson{at}perfuse.org
| Abstract |
|---|
|
|
|---|
Methods and Results As a substudy of the TIMI 10B trial (tissue plasminogen activator versus tenecteplase), 49 centers carried out 2-year follow-up. TIMI grade 2/3 flow (Cox hazard ratio [HR] 0.41, P=0.001), reduced CTFCs (faster flow, P=0.02), and an open microvasculature (TMPG 2/3) (HR 0.51, P=0.038) were all associated with improved 2-year survival. Rescue percutaneous coronary intervention (PCI) of closed arteries (TFG 0/1) at 90 minutes was associated with reduced mortality (P=0.03), and mortality trended lower with adjunctive PCI of open (TFG 2/3) arteries (P=0.11). In a multivariate model correcting for previously identified correlates of mortality (age, sex, pulse, left anterior descending coronary artery infarction, and any PCI during initial hospitalization), patency (TFG 2/3) (HR 0.32, P<0.001), CTFC (P=0.01), and TMPG 2/3 remained associated with reduced mortality (HR 0.46, P=0.02).
Conclusions Both improved epicardial flow (TFG 2/3 and low CTFCs) and tissue-level perfusion (TMPG 2/3) at 90 minutes after thrombolytic administration are independently associated with improved 2-year survival, suggesting complementary mechanisms of improved long-term survival. Although rescue PCI reduced long-term mortality, improved microvascular perfusion (TMPG 2/3) before PCI was also related to improved mortality independently of epicardial blood flow and the performance of rescue or adjunctive PCI. Further prospective trials are warranted to re-examine the benefit of early PCI with thrombolysis.
Key Words: perfusion blood flow trials myocardial infarction thrombolysis
| Introduction |
|---|
|
|
|---|
| Methods |
|---|
|
|
|---|
Percutaneous coronary intervention (PCI) was performed at the discretion of the clinical investigator and was not mandated by protocol in TIMI 10B. Rescue PCI was defined as PCI performed within 150 minutes of initial thrombolytic treatment for patients with TFG 0 or 1 at 90 minutes (n=120/150, 80%). Adjunctive PCI was defined as PCI performed within 150 minutes of thrombolytic treatment for patients with TFG 2 or 3 at 90 minutes (n=105/668, 15.7%). Delayed PCI was defined as first PCI performed beyond 150 minutes after thrombolytic treatment (n=235/593, 39.6%). Patients who experienced a recurrent myocardial infarction (MI) before PCI were analyzed as medically treated patients, because recurrent MI presumably led to their intervention (n=9).
Recurrent MI was defined as in previous TIMI trials, as follows.10 Within 18 hours of thrombolytic therapy, recurrent ischemic discomfort
30 minutes and new or recurrent ST-segment elevation
0.1 mV were required. After 18 hours, a criterion of re-elevation of creatine kinase (CK)-MB to above the upper limits of normal (ULN) and increased by
50% over the previous value was added. If quantitative CKMB was not available, it was required that the total CK be re-evaluated to more than twice the ULN and increased by
25% of
200 U/mL over the previous value; if re-elevated to less than twice normal, the CK was required to exceed the ULN by
50% and the previous value by 2-fold or
200 U/mL. After coronary angioplasty, the definition of recurrent infarction was new Q waves in
2 leads and re-elevation of the CKMB (or total CK if CKMB was not available) to at least twice normal and
50% above the previous value; after CABG, the latter criterion was set at a CKMB elevation
5 times normal.
Visual Assessment of Flow
All angiographic end points were prospectively assessed at 90 minutes. The TFG, as previously defined,1 was assessed at the TIMI angiographic core laboratory by a single observer (C.M.G.), who was blinded to treatment assignment and clinical outcome. The CTFC was converted when necessary to be based on the most common filming speed in the United States of 30 frames per second.7,8 The TMPGs were assessed as previously defined.9 In brief, in TMPG 0, there is minimal or no myocardial blush; in TMPG 1, dye stains the myocardium and this stain persists on the next injection; in TMPG 2, dye enters the myocardium but washes out slowly so that dye is strongly persistent at the end of the injection; and in TMPG 3, there is normal entrance and exit of dye in the myocardium so that dye is mildly persistent at the end of the injection.
Statistical Analysis
Analyses were performed with Stata statistical software version 7.0.11 Variables were compared by the Fishers exact test or
2 test for categorical data. Students t test or ANOVA was used for the analysis of normally distributed continuous variables. The nonparametric Wilcoxon rank sum test (for 2-way comparisons) or the Kruskal-Wallis test (for 3-way comparisons) was used to compare continuous variables when the data were not normally distributed or when data were imputed to an occluded vessel. The Cox hazard ratio (HR) model, Kaplan-Meier curves, and log-rank test were used in the survival analysis to test the equality of survival.
| Results |
|---|
|
|
|---|
|
Relation of TIMI Flow Indices to Mortality
TFG 2/3 (Cox HR 0.41, P=0.001), reduced CTFCs (faster flow) (HR 0.92 per 10-frame decrease, P=0.02), and an open microcirculation (TMPG 2/3) (HR 0.51, P=0.038) on the 90-minute angiogram were all associated with improved 2-year mortality in univariate analyses (Table 2, Figures 1 and 2), although TFG 3 was not (HR 0.68, P=0.12). An open microvasculature was also associated with reduced rates of death/MI (HR 0.64, P=0.044), whereas other parameters were not related to the end point of death or MI (Table 3). In a multivariate model correcting for previously identified correlates of death (age, sex, pulse, left anterior descending coronary artery infarction, and any PCI during initial hospitalization), the 90-minute patency (TFG 2/3) (HR 0.32, P<0.001), CTFC (HR 0.90 per 10-frame decrease, P=0.01), and TMPG 2/3 remained associated with reduced mortality (HR 0.46, P=0.02).
|
|
|
|
Relation of PCI and Mortality
On univariate analysis, rescue PCI of closed arteries (TFG 0/1) was associated with improved mortality (log-rank P=0.031), whereas adjunctive PCI of open arteries (TFG 2/3) tended to be associated with lower long-term mortality (P=0.11), but delayed PCI did not (P=0.36) (Figures 3 and 4). The number of patients who received stents was not significantly different for patients who underwent delayed and adjunctive PCI (48% and 38%) but was higher for each of these than in patients who underwent rescue PCI (21%, P<0.005). After adjustment for use of stent (P=NS), rescue PCI remained associated with 2-year mortality in patients with closed arteries (HR 0.34, P=0.03), and a trend was seen for improved mortality in adjunctive (HR 0.31, P=0.070) and delayed (HR 0.49, P=0.15) PCI.
|
|
| Discussion |
|---|
|
|
|---|
Long-Term Mortality Benefits of Rescue and Adjunctive PCI
As an adjunct to thrombolysis, PCI might improve flow, relieve residual stenoses, and reduce reocclusion. Despite these intuitive angiographic benefits, early randomized trials of adjunctive PCI in open vessels1214 and nonrandomized trials of rescue PCI in closed vessels1517 did not show a clinical benefit of angioplasty routinely performed immediately after thrombolysis over thrombolysis alone, probably because of a higher risk of intramural hemorrhage in the arterial wall and abrupt closure.1217 These trials are now outdated, because they preceded the widespread use of stents, aspirin, ticlopidine/clopidogrel, GP IIb/IIIA inhibitors, and the monitoring of activated clotting times. The recent Primary Angioplasty Alteplase Compatibility Trial (PACT) incorporated these current practice patterns and demonstrated that the 2 strategies (half dose of tissue plasminogen activator plus intervention) can be combined without increased risk of adverse outcomes over intervention alone.18 Schweiger et al19 also recently showed that in the TIMI 10B and 14 trials, which incorporated current practice patterns, patients with TFG 0 or 1 who underwent rescue PCI had lower 30-day mortality than those treated without PCI (6% versus 17%, P=0.01). The 30-day mortality of adjunctive PCI patients (3%) was similar to that of patients undergoing delayed PCI.19
Although previous studies of rescue/adjunctive PCI reported in-hospital or 30-day mortality,1219 the long-term follow-up reported here indicates that in the era of stenting, GP IIb/IIIA inhibition, and newer antiplatelet agents, patients undergoing rescue PCI for a closed vessel (TFG 0/1) have improved 2-year mortality compared with those not treated with a mechanical intervention. Only 3.1% of patients (18/583) were treated with a GP IIb/IIIA inhibitor, and none of these patients died. The favorable outcomes among patients treated with either adjunctive or rescue PCI may obscure differences in clinical outcomes among pharmacological regimens.
The TMPG was related to 2-year mortality independently of whether the patient underwent PCI. Recently, Stone et al20 also reported that myocardial blush provides in-hospital prognostic information in those patients undergoing either primary or rescue PCI. Even among patients with epicardial TFG 3 at the completion of the PCI, there was a significant gradient in in-hospital mortality, depending on the myocardial blush grade in the study by Stone et al.20 Our data now extend these initial observations to show the complementary benefit of complete epicardial flow and myocardial perfusion on long-term survival. Taken together, these angiographic data add to a growing body of literature linking impaired tissue-level perfusion on echocardiography or electrocardiography to adverse clinical outcomes in the acute MI setting.2126
Limitations
The reproducibility of the TMPG remains to be determined. Although 90-minute myocardial perfusion and epicardial coronary blood flow are both related to mortality, there are other causes of death that may be unrelated to 90-minute perfusion, such as intracranial hemorrhage, reinfarction, ventricular arrhythmias, and mechanical complications. Although rescue PCI was related to long-term outcomes, the impact of measured and unmeasured confounders may not have been adequately controlled for.
Conclusions
Three simple, readily available angiographic methods to assess angiographic outcomes are all related to long-term mortality at 2 years. After administration of thrombolytics in patients with acute MI, impaired perfusion of the myocardium on coronary arteriography as assessed by the TMPG is related to a higher risk of mortality that is independent of flow in the epicardial artery. The use of the TMPG permits risk stratification, even among patients with TFG 3 and among those undergoing PCI. Randomized trials are warranted to re-examine the benefit of early PCI with thrombolysis.
| Acknowledgments |
|---|
Received December 28, 2001; revision received February 12, 2002; accepted February 12, 2002.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. J. Brener, D. J. Moliterno, P. E. Aylward, A. W.J. van't Hof, W. Ruzyllo, W. W. O'Neill, C. W. Hamm, C. M. Westerhout, C. B. Granger, P. W. Armstrong, et al. Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI Angiographic Study Eur. Heart J., May 1, 2008; 29(9): 1127 - 1135. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Stangl, V. Witzel, G. Baumann, and K. Stangl Current diagnostic concepts to detect coronary artery disease in women Eur. Heart J., March 2, 2008; 29(6): 707 - 717. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Seyfeli, A. Abaci, M. Kula, R. Topsakal, N. K. Eryol, H. Arinc, I. Ozdogru, and A. Ergin Myocardial Blush Grade: To Evaluate Myocardial Viability in Patients With Acute Myocardial Infarction Angiology, November 1, 2007; 58(5): 556 - 560. [Abstract] [PDF] |
||||
![]() |
J P Greenwood, J F Younger, J P Ridgway, M U Sivananthan, S G Ball, and S Plein Safety and diagnostic accuracy of stress cardiac magnetic resonance imaging vs exercise tolerance testing early after acute ST elevation myocardial infarction Heart, November 1, 2007; 93(11): 1363 - 1368. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Marques, P. Knaapen, R. Boellaard, N. Westerhof, A. A. Lammertsma, C. A. Visser, and F. C. Visser Hyperaemic microvascular resistance is not increased in viable myocardium after chronic myocardial infarction Eur. Heart J., October 1, 2007; 28(19): 2320 - 2325. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Fernandez-Aviles, J. J. Alonso, G. Pena, J. Blanco, J. Alonso-Briales, J. Lopez-Mesa, F. Fernandez-Vazquez, J. Moreu, R. A. Hernandez, A. Castro-Beiras, et al. Primary angioplasty vs. early routine post-fibrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the GRACIA-2 non-inferiority, randomized, controlled trial Eur. Heart J., April 2, 2007; 28(8): 949 - 960. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. G. Camici and F. Crea Coronary Microvascular Dysfunction N. Engl. J. Med., February 22, 2007; 356(8): 830 - 840. [Full Text] [PDF] |
||||
![]() |
M. Mariani, R. Fetiveau, E. Rossetti, A. Poli, F. Poletti, P. Vandoni, M. D'Urbano, F. Cafiero, G. Mariani, C. Klersy, et al. Significance of total and differential leucocyte count in patients with acute myocardial infarction treated with primary coronary angioplasty Eur. Heart J., November 1, 2006; 27(21): 2511 - 2515. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. B. Borden and D. P. Faxon Facilitated Percutaneous Coronary Intervention J. Am. Coll. Cardiol., September 19, 2006; 48(6): 1120 - 1128. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Gibson, D. A. Morrow, S. A. Murphy, T. M. Palabrica, L. K. Jennings, P. H. Stone, H. H. Lui, T. Bulle, N. Lakkis, R. Kovach, et al. A Randomized Trial to Evaluate the Relative Protection Against Post-Percutaneous Coronary Intervention Microvascular Dysfunction, Ischemia, and Inflammation Among Antiplatelet and Antithrombotic Agents: The PROTECT-TIMI-30 Trial J. Am. Coll. Cardiol., June 20, 2006; 47(12): 2364 - 2373. [Abstract] [Full Text] [PDF] |
||||
![]() |
E Perez-David, M A Garcia-Fernandez, J Quiles, P Mahia, J L Lopez-Sendon, E Lopez de Sa, M J Ledesma, M Moreno, M Desco, and E Garcia Usefulness of quantitative myocardial contrast echocardiography for prediction of ventricular function recovery after myocardial infarction treated with primary angioplasty. Heart, May 1, 2006; 92(5): 693 - 694. [Full Text] [PDF] |
||||
![]() |
P. G. Steg, L. Francois, B. Iung, D. Himbert, P. Aubry, P. Charlier, H. Benamer, L. J. Feldman, and J.-M. Juliard Long-term clinical outcomes after rescue angioplasty are not different from those of successful thrombolysis for acute myocardial infarction Eur. Heart J., September 2, 2005; 26(18): 1831 - 1837. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Mizote, Y. Ueda, T. Ohtani, M. Shimizu, Y. Takeda, T. Oka, M. Tsujimoto, A. Hirayama, M. Hori, and K. Kodama Distal Protection Improved Reperfusion and Reduced Left Ventricular Dysfunction in Patients With Acute Myocardial Infarction Who Had Angioscopically Defined Ruptured Plaque Circulation, August 16, 2005; 112(7): 1001 - 1007. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Gibson, A. J. Kirtane, K. Boundy, H. Ly, D. Karmpaliotis, S. A. Murphy, R. P. Giugliano, C. P. Cannon, E. M. Antman, E. Braunwald, et al. Association of a negative residual stenosis following rescue/adjunctive percutaneous coronary intervention with impaired myocardial perfusion and adverse outcomes among ST-segment elevation myocardial infarction patients J. Am. Coll. Cardiol., February 1, 2005; 45(3): 357 - 362. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y Ohara, Y Hiasa, T Takahashi, K Yamaguchi, R Ogura, T Ogata, K Yuba, K Kusunoki, S Hosokawa, K Kishi, et al. Relation between the TIMI frame count and the degree of microvascular injury after primary coronary angioplasty in patients with acute anterior myocardial infarction Heart, January 1, 2005; 91(1): 64 - 67. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Gibson, S. A. Murphy, A. J. Kirtane, R. P. Giugliano, C. P. Cannon, E. M. Antman, E. Braunwald, and TIMI Study Group Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with st-segment elevation myocardial infarction J. Am. Coll. Cardiol., September 1, 2004; 44(5): 980 - 987. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Iwakura, H. Ito, S. Kawano, A. Okamura, K. Tanaka, Y. Nishida, Y. Maekawa, and K. Fujii Assessing myocardial perfusion with the transthoracic Doppler technique in patients with reperfused anterior myocardial infarction: comparison with angiographic, enzymatic and electrocardiographic indices Eur. Heart J., September 1, 2004; 25(17): 1526 - 1533. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Gibson, L. K. Jennings, S. A. Murphy, D. P. Lorenz, R. P. Giugliano, R. A. Harrington, S. Cholera, R. Krishnan, R. M. Califf, E. Braunwald, et al. Association Between Platelet Receptor Occupancy After Eptifibatide (Integrilin) Therapy and Patency, Myocardial Perfusion, and ST-Segment Resolution Among Patients With ST-Segment-Elevation Myocardial Infarction: An INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) Substudy Circulation, August 10, 2004; 110(6): 679 - 684. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Grines and W. W. O'Neill Rescue angioplasty: Does the concept need to be rescued? J. Am. Coll. Cardiol., July 21, 2004; 44(2): 297 - 299. [Full Text] [PDF] |
||||
![]() |
C. M. Gibson and A. Schomig Coronary and Myocardial Angiography: Angiographic Assessment of Both Epicardial and Myocardial Perfusion Circulation, June 29, 2004; 109(25): 3096 - 3105. [Full Text] [PDF] |
||||
![]() |
W. F. Fearon, W. Aarnoudse, N. H.J. Pijls, B. De Bruyne, L. B. Balsam, D. T. Cooke, R. C. Robbins, P. J. Fitzgerald, A. C. Yeung, and P. G. Yock Microvascular Resistance Is Not Influenced by Epicardial Coronary Artery Stenosis Severity: Experimental Validation Circulation, May 18, 2004; 109(19): 2269 - 2272. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Gibson Confusion in reperfusion J. Am. Coll. Cardiol., October 1, 2003; 42(7): 1186 - 1187. [Full Text] [PDF] |
||||
![]() |
C. M. Gibson Has My Patient Achieved Adequate Myocardial Reperfusion? Circulation, August 5, 2003; 108(5): 504 - 507. [Full Text] [PDF] |
||||
![]() |
C. M. Gibson, J. Karha, S. A. Murphy, D. James, D. A. Morrow, C. P. Cannon, R. P. Giugliano, E. M. Antman, E. Braunwald, and TIMI Study Group Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the thrombolysis in myocardial infarction trials J. Am. Coll. Cardiol., July 2, 2003; 42(1): 7 - 16. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P.S. Henriques, F. Zijlstra, A. W.J. van 't Hof, M.-J. de Boer, J.-H. E. Dambrink, M. Gosselink, J. C.A. Hoorntje, and H. Suryapranata Angiographic Assessment of Reperfusion in Acute Myocardial Infarction by Myocardial Blush Grade Circulation, April 29, 2003; 107(16): 2115 - 2119. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. P. Lee, N. A. Herity, B. L. Hiatt, W. F. Fearon, M. Rezaee, A. J. Carter, M. Huston, D. Schreiber, P. M. DiBattiste, and A. C. Yeung Adjunctive Platelet Glycoprotein IIb/IIIa Receptor Inhibition With Tirofiban Before Primary Angioplasty Improves Angiographic Outcomes: Results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) Pilot Trial Circulation, March 25, 2003; 107(11): 1497 - 1501. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Dibra, J. Mehilli, J. Dirschinger, J.u. Pache, J. Neverve, M. Schwaiger, A. Schomig, and A. Kastrati Thrombolysis in myocardial infarction myocardial perfusion grade in angiography correlates with myocardial salvage in patients with acute myocardial infarction treated with stenting or thrombolysis J. Am. Coll. Cardiol., March 19, 2003; 41(6): 925 - 929. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. K. Haager, P. Christott, N. Heussen, W. Lepper, P. Hanrath, and R. Hoffmann Prediction of clinical outcome after mechanical revascularization in acute myocardial infarction by markers of myocardial reperfusion J. Am. Coll. Cardiol., February 19, 2003; 41(4): 532 - 538. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Kern Patterns of Left Ventricular Dilatation With an Opened Artery After Acute Myocardial Infarction: Missing Links to Long-Term Prognosis Circulation, October 29, 2002; 106(18): 2294 - 2295. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||